Robert C. Doebele, MD, PhD, associate professor in the Division of Medical Oncology at the University of Colorado, discusses the significance of brain metastases in patients with non–small cell lung cancer.
Robert C. Doebele, MD, PhD, associate professor in the Division of Medical Oncology at the University of Colorado, discusses the significance of brain metastases in patients with nonsmall cell lung cancer (NCSLC).
The current standard of care for patients with NCSLC is crizotinib (Xalkori), but this treatment does not have a high response rate and does not allow for good control of brain metastases. Entrectinib (RXDX-101) is currently being tested in clinical trials and has proven to have better control on brain metastases.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More